ArticleBMC cancer2017

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.

Hai-Liang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.